Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab-rezetecan followed by fluzoparib as second-line maintenance for platinum-sensitive recurrent ovarian cancer after first-line PARPi
ChiCTR2600122034Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan and fluzoparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
trastuzumab rezetecanfluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Endometrioid Cystadenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600122034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122034.